
THRA is a synthetic peptide investigated in laboratory models as an agonist at the GLP-1, GIP and glucagon receptors. Research interest centres on incretin receptor pharmacology, comparative selectivity across the three targets, and downstream cyclic AMP signalling in transfected cell lines.
Presentation
Synthetic · Manufactured
Supplied as a lyophilized powder requiring reconstitution with a suitable diluent for research purposes only. Not for human consumption. Not approved for diagnostic, therapeutic, or veterinary use.
The following is drawn from preclinical research literature and is provided for informational purposes only. It does not constitute medical advice or imply therapeutic outcomes.
99+ is committed to providing researchers with clearly identified compounds and accessible analytical documentation. Where applicable, product-specific Certificates of Analysis are available so researchers can review the analytical results associated with individual lots.
A Certificate of Analysis is on file for this compound. Open it to review the reported identity and purity results and the laboratory that issued them.
Other compounds in the catalog, each assayed on its own lot.